In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Biotech Religion Invaded by Investor Skeptics

Executive Summary

It has taken months for biotech's March madness to calm back into something like sanity, doing so in the context of Nasdaq's overall downward spiral. But if there was one lesson to the volume of recent financings it was this: the big can get bigger; the small-and the early-stage-should be just a teeny bit worried. The large and highly valued companies, particularly those with drugs on or about to be on the market can raise money easily. But new discovery-stage offerings have had trouble--like Rigel's. IPO buyers have instead opted for the apparently lower-risk, faster-return businesses of nearer-term companies like drug-delivery and service firms.

You may also be interested in...



Meet the Market, As It Is: Amphora Emphasizes Risk Reduction

There are many ways start-ups can lower the risks of doing business in the current climate. Amphora's approach will likely include working for hire to cool cash burn while building relationships with skittish clients; leveraging assets that have ripened beyond the research phase; and helping customers reduce the risks they confront.

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel